Jim Cramer on Olema Pharmaceuticals: "Too Risky for Me"

Jim Cramer considers Olema Pharmaceuticals "too risky" for investment due to the potential for significant losses in the current market. The company reported Q4 GAAP EPS of -$0.50 and a net loss of $162.5 million for FY25. Cramer acknowledges the potential of OLMA, but suggests that other AI stocks may offer greater upside potential with less downside risk.